Garcinol acts as a degradation device to reduce the suppressive activity of regulatory T cells (44) and to enhance the in vivo antitumor activity of a targeted therapeutic anti-p185(her2/neu) (ERBB2) antibody in MMTV-neu transgenics implanted with neu transformed breast tumor cells [83]. The gene discussed is ERBB2; the disease is breast neoplasm.